Clinical Validation of Histotype Px® Colorectal Selected for Oral Presentation at ESMO 2025
OSLO – October 15, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, is pleased to announce that data from a Dutch nationwide clinical validation study have been selected for oral presentation at the upcoming ESMO Congress 2025 in Berlin. The presentation will take place on Monday, October 20, in the Proffered paper session: AI & digital oncology.
The interim analysis highlights the prognostic value of Histotype Px® Colorectal in patients with high-risk stage II and stage III colon cancer eligible for adjuvant chemotherapy (ACT), but who did not receive ACT. Conducted in collaboration with University Medical Center Utrecht and the Institute for Cancer Genetics and Informatics at Oslo University Hospital, the retrospective study analyzed digital H&E slides from 453 patients across 65 hospitals in the Netherlands.
Histotype Px® Colorectal successfully stratified patients into distinct risk groups – low, intermediate, and high – with a 3-year cancer-specific survival (CSS) of 93.7% observed in the low-risk group (n=215), consisting of nearly half of all patients. High-risk patients had a 3-year CSS of 60.4%, constituting 18% of the cases. These findings demonstrate the potential of Histotype Px® Colorectal as a readily available and affordable AI biomarker to guide personalized treatment decisions, helping patients avoid unnecessary chemotherapy and identifying those who may benefit from more intensive therapy.
Dr. Janine Roodhart, Associate Professor and Oncologist at Department of Medical Oncology, UMC Utrecht:
"This study is analyzing Histotype Px® Colorectal and its ability to distinguish between patients who have great outcomes after surgery alone and those at higher risk of recurrence who are likely to benefit from ACT. By implementing biomarkers such as Histotype Px® Colorectal we may be able to spare many patients the burden of chemotherapy, while focusing resources on those who truly benefit from additional treatment. Next step is to compare this cohort of patients who did not receive ACT with a similar cohort of patients who did receive ACT, to assess the potential benefit of ACT in each of the risk groups."
"Being selected for oral presentation at ESMO 2025 underlines the growing importance and relevance of AI-powered digital biomarkers as a transformative diagnostic modality in precision oncology. Histotype Px® is designed to be implemented on digitized routine histology slides, making it widely accessible and scalable," added Torbjørn Furuseth, CEO and Co-founder of DoMore Diagnostics.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com